Back to Agenda
Session 3: How Could The JCA Procedure Drive Positive Change? (Roundtable Discussions)
Session Chair(s)
Matias Olsen, MA
Senior Manager, Public Affairs & Policy , European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Belgium
Valentina Strammiello, MA
Director of Programmes, European Patients' Forum, Belgium
This Session will reflect on the JCA and how can it drive positive change. With a focus on Oncology and ATMPs as the first products in line for EU HTA, participants will be invited to explore though interactive roundtable discussions critical aspects for the implementation of the JCA, such as:
Roundtable 1: How can we ensure the workability of the new system?
Roundtable 2: Evidence generation and assessment methods for Oncology products and ATMPs (which may include OMPs)
Speaker(s)
Anne Willemsen, MSC
Senior Project Manager, Joint Production Co-Lead Partner - Pharmaceuticals, ZIN - National Health Care Institute, Netherlands
Key Elements of the JCA Process
Patrick Hopkinson
Vice President WW Health Economics & Outcomes Research, Bristol Myers Squibb, United Kingdom
Industry Perspective on Workability
Murray Aitken, MBA
Executive Director, IQVIA Institute for Human Data Science, United States
Highlights of Oncology Trends Report 2023
Francesca Cerreta, PHARMD, MPHARM, MS
Principal Scientific Officer, European Medicines Agency, Netherlands
Regulatory Outlook and Challenges in the Areas of Oncology and ATMPs
Have an account?